Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reiss

Showing results (331-340 of 509) with videos related to

Pageof 51
Sort By:
BMC Infectious Diseases|June 3, 2021
Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional studySaskia J Bogers, Maarten F Schim van der Loeff, Udi Davidovich, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 3, 2003
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance studyEmma L Hammond, David Sayer, David Nolan, et al.
Scientific Reports|December 19, 2022
The experienced positive and negative influence of HIV on quality of life of people with HIV and vulnerable to HIV in the NetherlandsKim A G J Romijnders, Laura de Groot, Sigrid C J M Vervoort, et al.
Journal of the International AIDS Society|June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µLAndrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
AIDS (London, England)|May 16, 2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesMargaret May, Jonathan A C Sterne, Caroline Sabin, et al.
AIDS (London, England)|October 28, 2022
HIV transmission among acutely infected participants of a Dutch cohort study 2015-2021 is not associated with large, clustered outbreaksHenrieke A B Prins, Casper Rokx, Annelies Verbon, et al.
BMC Medicine|April 3, 2016
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaborationCaroline A Sabin, Peter Reiss, Lene Ryom, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
The Lancet. Healthy Longevity|September 13, 2022
Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGE<sub>h</sub>IV cohort studySebastiaan O Verboeket, Anders Boyd, Ferdinand W Wit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Pageof 51

Showing results (331-340 of 509) with videos related to

Sort By:
Pageof 51
BMC Infectious Diseases|June 3, 2021
Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional studySaskia J Bogers, Maarten F Schim van der Loeff, Udi Davidovich, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 3, 2003
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance studyEmma L Hammond, David Sayer, David Nolan, et al.
Scientific Reports|December 19, 2022
The experienced positive and negative influence of HIV on quality of life of people with HIV and vulnerable to HIV in the NetherlandsKim A G J Romijnders, Laura de Groot, Sigrid C J M Vervoort, et al.
Journal of the International AIDS Society|June 12, 2021
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µLAndrew Atkinson, Jose M Miro, Amanda Mocroft, et al.
AIDS (London, England)|May 16, 2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesMargaret May, Jonathan A C Sterne, Caroline Sabin, et al.
AIDS (London, England)|October 28, 2022
HIV transmission among acutely infected participants of a Dutch cohort study 2015-2021 is not associated with large, clustered outbreaksHenrieke A B Prins, Casper Rokx, Annelies Verbon, et al.
BMC Medicine|April 3, 2016
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaborationCaroline A Sabin, Peter Reiss, Lene Ryom, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
The Lancet. Healthy Longevity|September 13, 2022
Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGE<sub>h</sub>IV cohort studySebastiaan O Verboeket, Anders Boyd, Ferdinand W Wit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2010
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?, Amanda Mocroft, Peter Reiss, et al.
Pageof 51